Clinical Trials Browser

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT02389842 2024-09-26

PIPA

Phase 1 Completed

79 enrolled

Breast

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast

Breast Neoplasms

NCT02913430 2024-09-23

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Phase EARLY_PHASE1 Completed

7 enrolled 13 charts

Breast

Breast Neoplasms

NCT04176354 2024-08-23

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Completed

813 enrolled 11 charts

Breast

Breast Neoplasms

NCT03981614 2024-08-22

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Phase 2 Completed

102 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT03560531 2024-08-09

A Study of ZN-c5 in Subjects With Breast Cancer

Phase 1/2 Completed

181 enrolled 36 charts

Breast

Breast Neoplasms

NCT05361655 2024-06-07

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Completed

2,888 enrolled 17 charts

Breast

Breast Neoplasms

NCT02599714 2024-06-06

PASTOR

Phase 1 Completed

54 enrolled

Breast

Breast Neoplasms

NCT06003114 2024-05-16

A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Completed

472 enrolled

Breast

Breast Neoplasms

NCT02448420 2024-04-18

PATRICIA II

Phase 2 Completed

73 enrolled

Breast

Breast Neoplasms

NCT06367335 2024-04-16

ETIC

Completed

128 enrolled

DILI

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

55 enrolled 15 charts

Breast

Breast Neoplasms

NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Phase 1 Completed

60 enrolled

Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

NCT02536742 2024-02-26

PYTHIA

Phase 2 Completed

124 enrolled 10 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03936270 2024-02-20

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

Phase 2 Completed

43 enrolled

Gynecologic

Ovarian Neoplasms

NCT02101034 2023-12-21

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Phase 1/2 Completed

96 enrolled 17 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05584644 2023-12-19

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Completed

150 enrolled 26 charts

Breast

Breast Neoplasms

NCT01864746 2023-12-12

PENELOPE-B

Phase 3 Completed

1,250 enrolled 12 charts

Breast

Breast Neoplasms

NCT03054363 2023-11-13

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Phase 1/2 Completed

42 enrolled 16 charts

Breast

Breast Neoplasms

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Phase 1 Completed

71 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

Clinical Trials

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

PADA-1

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

CYCLIGIST

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

ASPIRE

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

TOUCH

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

PARSIFAL

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

PALOMA-2

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

PIPA

PEARL

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

A Study of ZN-c5 in Subjects With Breast Cancer

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

PASTOR

A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

PATRICIA II

ETIC

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

PYTHIA

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

PENELOPE-B

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors